This expansion includes up to three additional targets focused on host factors for SARS-CoV-2, including ACE2 and TMPRSS2, both of which are considered critical for viral entry, with
Zymeworks will receive a payment under its collaboration with BeiGene as a result of the achievement of this development milestone. “To date, ZW25 has demonstrated promising activity in
The parties, which have signed a partnership and license agreement, have agreed to discover, develop, manufacture, and commercialise fully human neutralising monoclonal antibodies to address the COVID-19 pandemic.
The submission is based on results from the pivotal Phase 2 KarMMa study. The KarMMa study evaluated the efficacy and safety of ide-cel in heavily pre-treated patients with
The company has initiated an additional research and development project targeting the coronavirus group and has wrapped up initial screening under the repurposed and new drug discovery platform
The approval by the US Food and Drug Administration was based on positive results from the Phase III CASPIAN trial showing IMFINZI in combination with SoC platinum-etoposide demonstrated a
Compared to placebo, vericiguat in combination with available heart failure therapies, significantly cut down the risk of heart failure hospitalisation or cardiovascular death, which was the primary endpoint
This decision is being taken due to the urgent shift among clinical sites toward efforts to combat the COVID-19 pandemic, which has impacted the feasibility of completing the
Viralym-M is the company’s lead allogeneic, off-the-shelf, multi-virus specific T-cell therapy, being developed for the treatment and prevention of serious viral diseases caused by six commonly occurring, devastating
IPI-549 is an oral immuno-oncology candidate which has been designed to preferentially inhibit PI3K-gamma. The FDA fast track designation will enable the development and accelerate the review of
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.